UPDATE - BriaCell Files Coronavirus Immunotherapy Patent
April 14 2020 - 10:25AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has filed a provisional patent
application with the U.S. Patent and Trademark Office (USPTO)
outlining certain features thought to expand the clinical
applications of BriaCell’s genetically engineered whole-cell
immunotherapies to those of infectious diseases including the
SARS-CoV-2 virus that causes Coronavirus Disease 2019 (COVID-19).
The patent application, entitled “INDUCING
IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO
ANTIGEN-PRESENTING CELLS”, is based on molecular analyses of the
Company’s lead anti-tumor product candidate.
Antigen-presenting cells are the cells that
typically start immune responses. BriaCell’s whole-cell
immunotherapies are designed to stimulate the immune system to
recognize and destroy the patient’s tumors by acting as
antigen-presenting cells that turn on cancer cell-recognizing
immune cells from the patient. The new patent application by
BriaCell scientists expands on this paradigm by proposing
additional cellular therapeutics designed to activate immune cells
recognizing SARS-CoV-2 (the coronavirus causing COVID-19)
antigens.
The patent application seeks protection for,
among others, new whole-cell therapeutics and methods for their
use.
The Company cautions that COVID-19 vaccine
development is still under early-stage research and development and
is not making any express or implied claims that it has the ability
to prevent or eliminate the COVID-19 virus at this time.
The Company’s scientific experts have read and
approved the scientific disclosures contained in the press
release.
About Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019, abbreviated as
COVID-19, refers to a new disease, caused by a novel (or new)
coronavirus that has not previously been seen in humans. The novel
coronavirus is also called severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV).
The clinical spectrum of SARS-CoV-2 infection appears to be
wide, ranging from asymptomatic infection, and mild upper
respiratory tract illness to severe viral pneumonia with
respiratory failure and even death, with many patients being
hospitalized with pneumonia.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to
known and unknown risks relevant to the Company in particular
and to the biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024